The U.S. Food and Drug Administration has granted the third orphan drug designation (ODD) for OCU400 (Ocugen, Inc) in the treatment of RHO mutation-associated retinal degeneration, according to a press release.

 “OCU400, comprising the nuclear hormone receptor gene NR2E3, has the potential to help modulate numerous biological pathways that function in maintaining the health of the retina. A recent preclinical study published in Nature Gene Therapy demonstrated the potency of NR2E3 to elicit broad-spectrum therapeutic benefits in early and…

View Conference Coverage

Take a look at some of our conference coverage, visit our roundup section.

Journal Scan